XTX Topco Ltd Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

XTX Topco Ltd purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the second quarter, Holdings Channel reports. The institutional investor purchased 7,386 shares of the specialty pharmaceutical company’s stock, valued at approximately $788,000.

A number of other hedge funds have also modified their holdings of the company. Seven Eight Capital LP acquired a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $686,000. Hsbc Holdings PLC raised its position in shares of Jazz Pharmaceuticals by 49.6% in the 2nd quarter. Hsbc Holdings PLC now owns 45,344 shares of the specialty pharmaceutical company’s stock valued at $4,894,000 after acquiring an additional 15,041 shares during the period. Vanguard Personalized Indexing Management LLC raised its position in shares of Jazz Pharmaceuticals by 37.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,239 shares of the specialty pharmaceutical company’s stock valued at $664,000 after acquiring an additional 1,706 shares during the period. Mercer Global Advisors Inc. ADV raised its position in shares of Jazz Pharmaceuticals by 51.7% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 3,485 shares of the specialty pharmaceutical company’s stock valued at $372,000 after acquiring an additional 1,187 shares during the period. Finally, Amalgamated Bank raised its holdings in Jazz Pharmaceuticals by 4.7% during the 2nd quarter. Amalgamated Bank now owns 39,125 shares of the specialty pharmaceutical company’s stock worth $4,176,000 after buying an additional 1,745 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $110.76 on Monday. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $137.38. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The firm has a fifty day simple moving average of $110.79 and a 200 day simple moving average of $111.00. The stock has a market capitalization of $6.98 billion, a PE ratio of 22.84, a P/E/G ratio of 1.31 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. On average, research analysts expect that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the topic of several research analyst reports. Piper Sandler dropped their target price on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Wells Fargo & Company dropped their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Morgan Stanley dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $173.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.